1
|
Rhu J, Choi GS, Kwon CHD, Kim JM, Joh JW. Learning curve of laparoscopic living donor right hepatectomy. Br J Surg 2019; 107:278-288. [DOI: 10.1002/bjs.11350] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 06/07/2019] [Accepted: 08/05/2019] [Indexed: 12/28/2022]
Abstract
Abstract
Background
The feasibility and learning curve of laparoscopic living donor right hepatectomy was assessed.
Methods
Donors who underwent right hepatectomy performed by a single surgeon were reviewed. Comparisons between open and laparoscopy regarding operative outcomes, including number of bile duct openings in the graft, were performed using propensity score matching.
Results
From 2014 to 2018, 103 and 96 donors underwent laparoscopic and open living donor right hepatectomy respectively, of whom 64 donors from each group were matched. Mean(s.d.) duration of operation (252·2(41·9) versus 304·4(66·5) min; P < 0·001) and median duration of hospital stay (8 versus 10 days; P = 0·002) were shorter in the laparoscopy group. There was no difference in complication rates of donors (P = 0·298) or recipients (P = 0·394) between the two groups. Total time for laparoscopy decreased linearly (R2 = 0·407, β = –0·914, P = 0·001), with the decrease starting after approximately 50 procedures when cases were divided into four quartiles (2nd versus 3rd quartile, P = 0·001; 3rd versus 4th quartile, P = 0·023). Although grafts with bile duct openings were more abundant in the laparoscopy group (P = 0·022), no difference was found in the last two quartiles (P = 0·207).
Conclusion
Laparoscopic living donor right hepatectomy is feasible and an experience of approximately 50 cases may surpass the learning curve.
Collapse
Affiliation(s)
- J Rhu
- Department of Surgery, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - G-S Choi
- Department of Surgery, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - C H D Kwon
- Department of General Surgery, Digestive Disease and Surgery Institute, Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio, USA
| | - J M Kim
- Department of Surgery, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J-W Joh
- Department of Surgery, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
2
|
Rhu J, Choi GS, Kim JM, Kwon CHD, Kim SJ, Joh JW. Laparoscopic right posterior sectionectomy versus laparoscopic right hemihepatectomy for hepatocellular carcinoma in posterior segments: Propensity Score Matching Analysis. Scand J Surg 2018; 108:23-29. [PMID: 29973107 DOI: 10.1177/1457496918783720] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND AIMS: This study was designed to analyze the feasibility of laparoscopic right posterior sectionectomy compared to laparoscopic right hemihepatectomy in patients with hepatocellular carcinoma located in the posterior segments. MATERIAL AND METHODS: The study included patients who underwent either laparoscopic right posterior sectionectomy or laparoscopic right hemihepatectomy for hepatocellular carcinoma located in segment 6 or 7 from January 2009 to December 2016 at Samsung Medical Center. After 1:1 propensity score matching, patient baseline characteristics and operative and postoperative outcomes were compared between the two groups. Disease-free survival and overall survival were compared using Kaplan-Meier log-rank test. RESULTS: Among 61 patients with laparoscopic right posterior sectionectomy and 37 patients with laparoscopic right hemihepatectomy, 30 patients from each group were analyzed after propensity score matching. After matching, baseline characteristics of the two groups were similar including tumor size (3.4 ± 1.2 cm in laparoscopic right posterior sectionectomy vs 3.7 ± 2.1 cm in laparoscopic right hemihepatectomy, P = 0.483); differences were significant before matching (3.1 ± 1.3 cm in laparoscopic right posterior sectionectomy vs 4.3 ± 2.7 cm in laparoscopic right hemihepatectomy, P = 0.035). No significant differences were observed in operative and postoperative data except for free margin size (1.04 ± 0.71 cm in laparoscopic right posterior sectionectomy vs 2.95 ± 1.75 cm in laparoscopic right hemihepatectomy, P < 0.001). Disease-free survival (5-year survival: 38.0% in laparoscopic right posterior sectionectomy vs 47.0% in laparoscopic right hemihepatectomy, P = 0.510) and overall survival (5-year survival: 92.7% in laparoscopic right posterior sectionectomy vs 89.6% in laparoscopic right hemihepatectomy, P = 0.593) did not differ between the groups based on Kaplan-Meier log-rank test. CONCLUSION: For hepatocellular carcinoma in the posterior segments, laparoscopic right posterior sectionectomy was feasible compared to laparoscopic right hemihepatectomy when performed by experienced laparoscopic surgeons.
Collapse
Affiliation(s)
- J Rhu
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - G S Choi
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J M Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - C H D Kwon
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S J Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J-W Joh
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
3
|
Mo H, Kim Y, Rhu J, Lee K, Kim T, Im S, Lee E, Lee H, Moon H, Noh D, Han W. Actual conversion rate from total mastectomy to breast conservation after neoadjuvant chemotherapy for stages II—III breast cancer patients. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30468-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Lee ES, Han W, Kim Y, Rhu J, Park JH, Kim KE, Ju YW, Kim R, Lee HB, Moon HG, Noh DY. Abstract P4-06-18: Clinical application of multigene panel testing and genetic counseling for hereditary/familial breast cancer risk assessment: Prospective single center study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-06-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The identification of individuals at elevated risk for hereditary cancers has allowed the development of consensus recommendations for cancer screening and prevention. The introduction of multigene panels may identify more individuals with breast cancer gene mutations than does testing for BRCA1/2 alone. Therefore, the multigenerational panel increase the need for genetic counseling suggesting preventive approach or cancer-specific screening to patients and family members. The rapid clinical introduction of multigene panel testing, however, have several issues such as low- to moderate-risk gene mutations and clinical recommendations. We collect the mutation results and clinical recommendations after testing with multigene panel and giving genetic counseling.
Methods
We had developed multigene panel consisted of 64 genes related to hereditary cancer through previous study and prospectively enrolled 104 individuals who were appropriate candidates for hereditary breast cancer evaluation. The patients were tested with 64-gene panel(Celemics) and results were provided by us 4˜10 weeks later. We checked the family history of cancer and made a pedigree before testing.
Result
Among 104 participants, 26 patients harbored deleterious mutations, most commonly in high to moderate-risk breast/ovarian cancer genes (BRCA1/2, BRIP, RAD51 and RAD51D), Lynch syndrome gene(MSH6) and other genes(FH, SPINK1). We recommended the cancer-specific screening and/or preventive approach for mutation-positive patients and suggested additional genetic test for the family members. Among them, 6 (23%) patients received Risk reducing procedures (Prophylactic mastectomy or oophorectomy) and most of them(19 patients(73%)) received cancer specific screening.
Conclusion
We demonstrate the use of multigene panel testing for hereditary breast cancer and will suggest the process of the genetic counseling including indication and results analysis with multigene panel testing.
Citation Format: Lee E-S, Han W, Kim Y, Rhu J, Park JH, Kim K-E, Ju YW, Kim R, Lee H-B, Moon H-G, Noh D-Y. Clinical application of multigene panel testing and genetic counseling for hereditary/familial breast cancer risk assessment: Prospective single center study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-06-18.
Collapse
Affiliation(s)
- E-S Lee
- Seoul National University Hospital, Seoul, Republic of Korea
| | - W Han
- Seoul National University Hospital, Seoul, Republic of Korea
| | - Y Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - J Rhu
- Seoul National University Hospital, Seoul, Republic of Korea
| | - JH Park
- Seoul National University Hospital, Seoul, Republic of Korea
| | - K-E Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - YW Ju
- Seoul National University Hospital, Seoul, Republic of Korea
| | - R Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - H-B Lee
- Seoul National University Hospital, Seoul, Republic of Korea
| | - H-G Moon
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D-Y Noh
- Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
5
|
Park JH, Ju YW, Kim KE, Rhu J, Kim Y, Lee E, Lee HB, Moon HG, Noh DY, Han W. Abstract P3-01-14: Nomogram predicting axillary lymph node metastases to skip intraoperative analysis of sentinel lymph nodes. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-01-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: According to the American College of Surgeons Oncology Group Z0011 trial, complete axillary lymph node dissection (ALND) did not affect survival of patients with clinical T1-T2 invasive breast cancer and one to two sentinel lymph nodes (SLNs) metastases treated with lumpectomy, adjuvant systemic therapy, and radiation therapy. A significant proportion of breast cancer patients may not require ALND, in whom intraoperative analysis of SLNs can be omitted reducing operation time and cost. The aim of this study was to develop a nomogram predicting three or more axillary lymph nodes (ALNs) metastases based on preoperative imaging and clinicopathological factors.
Methods: The training set consisted of 1030 patients with clinical T1-T2 invasive breast cancer and clinically negative ALN who received surgery at Seoul National University Hospital (SNUH) between January 2010 and December 2013. Preoperative imaging techniques including ultrasonography (US), computed tomography (CT), positron emission tomography (PET), and clinicopathological features associated with three or more ALN metastases were evaluated by logistic regression analysis. A nomogram predicting three or more ALNs was developed with statistically significant factors. The validation set consisted of 781 independent patients who received surgery at SNUH between January 2014 and December 2015.
Results: Of the 1030 patients, 89 (8.6%) had three or more ALN metastases. Multivariate analysis showed that three or more ALN metastases was independently associated with tumor size (cm) by US (p<0.001), suspicious ALNs findings in US (p<0.001), chest CT (p<0.001), and PET/CT (≥ 1.4 SUV, p<0.001). Established nomogram evaluating the probability of three or more ALNs metastases includes the above four associated factors. The areas under the receiver operating characteristic (ROC) curve of the nomogram were 0.866 (95% confidence interval [CI] 0.826-0.905) for the training set and 0.867 (95% CI: 0.801-0.932) for the validation set. With cutoff point of 142, false negative ratio is 3.6%, and 8.6% of patients were candidates for intraoperative SLN analysis.
Conclusion: Patients with a strong possibility of three or more ALNs metastases can be identified using preoperative imaging methods including US, CT, and PET. The nomogram measuring this prospect may be valuable in skipping intraoperative analysis of SLNs with advantage of reduced operation time and cost.
Citation Format: Park JH, Ju YW, Kim KE, Rhu J, Kim Y, Lee E, Lee H-B, Moon H-G, Noh D-Y, Han W. Nomogram predicting axillary lymph node metastases to skip intraoperative analysis of sentinel lymph nodes [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-01-14.
Collapse
Affiliation(s)
- JH Park
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - YW Ju
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - KE Kim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - J Rhu
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Y Kim
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - E Lee
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - H-B Lee
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - H-G Moon
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - D-Y Noh
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - W Han
- Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
6
|
Lee HB, Kim M, Kang YJ, Lee ES, Rhu J, Noh DY, Moon HG, Kim S, Han W. Detection of spliceomic signatures for predicting endocrine resistance in estrogen receptor-positive breast cancer. Breast 2017. [DOI: 10.1016/s0960-9776(17)30154-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Lee ES, Kim J, Yoo TK, Kim Y, Han J, Kang YJ, Choi J, Rhu J, Lee HB, Han W, Noh DY, Moon HG. Abstract P6-07-19: An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-07-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose
We aimed to identify whether hormonal receptors change throughout tumor progression, because this may influence management and influence prognosis in breast cancer patients.
Patients and Methods
From the institution's database, we collected data of 963 patients who developed relapse during their follow-ups. To determine estrogen receptor(ER) and progesterone receptor (PR), we retrospectively reviewed immunohistochemical(IHC) results in both primary and relapsed tumors.
Results
Among a total of 963 patients, 280 and 683 patients experienced locoregional relapse only and distant metastasis irrespective of locoreginal relapse, respectively. ER in 650 patients and PR in 590 patients from both primary tumor and relapse were identified, revealing a change in 157 (24.2%) and 154 (26.1%) patients, respectively. In patients with distant metastasis, assessment of ER and PR showed an alteration in 86 and 56 patients, respectively. The overall survival related to the change of ER and PR status in primary tumor and relapse was significantly different (log rank, P<0.001 in both ER and PR status). In addition, women with hormone receptors negative primary tumors that changed to hormone receptors positive tumors who received anti-hormonal therapy after relapse showed a statistically significant good overall survival (p<0.001) compared with women who had constant ER-negative tumors.(cox regression, hazard ratio 2.32 ; 95% CI, 1.91 to 3.01)
Conclusion
The breast cancer showed alterations of hormone receptor status throughout tumor progression, hat were related to the strategy of treatment and significantly influences survival. Therefore, investigations of hormone receptor at relapse are essential and helpful in breast cancer patient management.
Citation Format: Lee E-S, Kim J, Yoo T-K, Kim Y, Han J, Kang YJ, Choi J, Rhu J, Lee H-B, Han W, Noh D-Y, Moon H-G. An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-19.
Collapse
Affiliation(s)
- E-S Lee
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - J Kim
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - T-K Yoo
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - Y Kim
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - J Han
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - YJ Kang
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - J Choi
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - J Rhu
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - H-B Lee
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - W Han
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - D-Y Noh
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| | - H-G Moon
- Seoul National University College of Medicine, Seoul, NU, Republic of Korea; SMG - SNU Boramae Medical Center, Seoul, NU, Republic of Korea; Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, NU, Republic of Korea
| |
Collapse
|